COO Maxwell sold 124,893 shares at blended $7.96, reducing stake by 15.5% to 680,465 shares
Donley Matthew Maxwell, Chief Operating Officer of Aurinia Pharmaceuticals (AUPH), executed 2 separate sales totaling 124,893 shares for $994,424.72 on March 3–4, 2025 at prices of $8.00 and $7.92, near the current price of $8.08. The sale represents a 15.5% reduction in his post-transaction holdings to 680,465 shares, a material but not complete exit. The company is trading -22.6% from its 52-week high of $10.44 and shows mixed recent momentum (-7.3% over 90 days but +1.6% over 30 days). Aurinia's fundamentals remain solid with annual revenue growth of +34.0% and a P/E of 17.96, though the timing of this concentrated sale during a period of relative weakness warrants investor monitoring of insider confidence signals and any broader strategic context.